Natera enters September with an unusual split: options traders are more defensive than they have been all year, even as the analyst community spent the past month lifting targets aggressively and the stock has climbed 19% in a month.
The sharpest signal this week is in options. Downside protection demand has pushed the put/call ratio to 1.50 — nearly two standard deviations above its 20-day average of 1.16, and right at the 52-week high of 1.51. That level of hedging is striking on a stock that just rallied hard off its August earnings beat. The ratio has been climbing consistently since late July, when it ran below 0.85, making the current defensive tilt a sustained trend rather than a one-day spike.
Short interest tells a less charged story. Bears hold 3.5% of the free float — a modest position that ticked up roughly 5% on the week but remains near the bottom of its range over the past two months. Borrowing costs are cheap at 0.46% annualised, up sharply on the week in percentage terms but still well within "easy borrow" territory. And availability is enormous: over 3,800% relative to shares already borrowed, meaning the lending market is essentially wide open. The borrow picture does not support a squeeze narrative or meaningful short-side conviction.
The Street is firmly in the bull camp. Following August's Q2 print — which drove a 17% single-day move — every major firm in the coverage universe raised its price target. JP Morgan lifted to $360, Citigroup moved to $365, Piper Sandler pushed to $363.50, and RBC went to $350. The mean target now sits at $338, fractionally above the current price of $328. That leaves almost no implied upside in consensus numbers, which may partly explain why options traders are reaching for puts even as ratings remain positive. Wells Fargo, at Equal-Weight with a $284 target, is the lone dissenting voice on valuation. The bull case centres on continued volume growth in Signatera MRD testing and expanding coverage decisions. Bears point to a still-negative net income — the company posted a net loss of $67M in Q2 — and the risk that reimbursement headwinds for its 22q test cap gross margin expansion below the 70% threshold management is targeting.
On the ownership side, the picture is incrementally constructive. BlackRock, JP Morgan Asset Management, and T. Rowe Price each hold roughly 7% of shares outstanding and all added modestly in the most recent reporting period. FMR (Fidelity) stands out — it added nearly 2.9 million shares as of July 31, one of the larger institutional accumulation moves in the register. No activist 13D is on file; the 13G holders are passive. Insider activity runs the other direction: the CEO, the President of Clinical Diagnostics, the Executive Chairman, and several directors have all sold in the past month, collectively moving more than $21M of stock in 90 days. Every sale is tagged as a pre-arranged 10b5-1 plan, so these are scheduled dispositions rather than discretionary signals — but the volume is worth noting at a stock near all-time highs.
The next earnings date is November 6. Given that August's print produced a 17% gap higher on the day and a further 13% over the following week, the November setup will matter. For now, the question is whether the put/call ratio clustering near 1.50 resolves through the stock drifting lower to where consensus targets offer more cushion, or through another round of target upgrades if near-term data points on Signatera uptake and reimbursement outcomes continue to land positively.
See the live data behind this article on ORTEX.
Open NTRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
